Gilead Sciences, Inc.(NASDAQ:GILD) shares gained 0.47% to $55.42. The company, on May 2, announced plans to initiate a third Phase 3 clinical trial of the company's investigational fixed-dose combination tablet of sofosbuvir and ledipasvir for the ...
Related articles »